Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Albrecht

Showing results (221-230 of 245) with videos related to

Pageof 25
Sort By:
Bioorganic & Medicinal Chemistry Letters|June 14, 2017
Inhibition of bromodomain-containing protein 9 for the prevention of epigenetically-defined drug resistanceTerry D Crawford, Steffan Vartanian, Alexandre Côté, et al.
The New England Journal of Medicine|July 24, 2009
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infectionJohn G McHutchison, Eric J Lawitz, Mitchell L Shiffman, et al.
Zeitschrift Fur Rheumatologie|August 30, 2012
[German 2012 guidelines for the sequential medical treatment of rheumatoid arthritis. Adapted EULAR recommendations and updated treatment algorithm]K Krüger, J Wollenhaupt, K Albrecht, et al.
Journal of Medicinal Chemistry|October 15, 2016
Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell LymphomasRishi G Vaswani, Victor S Gehling, Les A Dakin, et al.
Bioorganic & Medicinal Chemistry Letters|October 13, 2009
Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitorsAlessandro A Boezio, Loren Berry, Brian K Albrecht, et al.
Antiviral Therapy|February 15, 2013
Resistance-associated amino acid variants associated with boceprevir plus pegylated interferon-α2b and ribavirin in patients with chronic hepatitis C in the SPRINT-1 trialRobert A Ogert, John A Howe, John M Vierling, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery, Design, and Optimization of Isoxazole Azepine BET InhibitorsVictor S Gehling, Michael C Hewitt, Rishi G Vaswani, et al.
Journal of Medicinal Chemistry|January 27, 2007
Alkynylpyrimidine amide derivatives as potent, selective, and orally active inhibitors of Tie-2 kinaseVictor J Cee, Brian K Albrecht, Stephanie Geuns-Meyer, et al.
Journal of Medicinal Chemistry|January 28, 2016
Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical TrialsBrian K Albrecht, Victor S Gehling, Michael C Hewitt, et al.
Chemistry & Biology|December 3, 2014
EZH2 inhibitor efficacy in non-Hodgkin's lymphoma does not require suppression of H3K27 monomethylationWilliam D Bradley, Shilpi Arora, Jennifer Busby, et al.
Pageof 25

Showing results (221-230 of 245) with videos related to

Sort By:
Pageof 25
Bioorganic & Medicinal Chemistry Letters|June 14, 2017
Inhibition of bromodomain-containing protein 9 for the prevention of epigenetically-defined drug resistanceTerry D Crawford, Steffan Vartanian, Alexandre Côté, et al.
The New England Journal of Medicine|July 24, 2009
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infectionJohn G McHutchison, Eric J Lawitz, Mitchell L Shiffman, et al.
Zeitschrift Fur Rheumatologie|August 30, 2012
[German 2012 guidelines for the sequential medical treatment of rheumatoid arthritis. Adapted EULAR recommendations and updated treatment algorithm]K Krüger, J Wollenhaupt, K Albrecht, et al.
Journal of Medicinal Chemistry|October 15, 2016
Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell LymphomasRishi G Vaswani, Victor S Gehling, Les A Dakin, et al.
Bioorganic & Medicinal Chemistry Letters|October 13, 2009
Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitorsAlessandro A Boezio, Loren Berry, Brian K Albrecht, et al.
Antiviral Therapy|February 15, 2013
Resistance-associated amino acid variants associated with boceprevir plus pegylated interferon-α2b and ribavirin in patients with chronic hepatitis C in the SPRINT-1 trialRobert A Ogert, John A Howe, John M Vierling, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery, Design, and Optimization of Isoxazole Azepine BET InhibitorsVictor S Gehling, Michael C Hewitt, Rishi G Vaswani, et al.
Journal of Medicinal Chemistry|January 27, 2007
Alkynylpyrimidine amide derivatives as potent, selective, and orally active inhibitors of Tie-2 kinaseVictor J Cee, Brian K Albrecht, Stephanie Geuns-Meyer, et al.
Journal of Medicinal Chemistry|January 28, 2016
Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical TrialsBrian K Albrecht, Victor S Gehling, Michael C Hewitt, et al.
Chemistry & Biology|December 3, 2014
EZH2 inhibitor efficacy in non-Hodgkin's lymphoma does not require suppression of H3K27 monomethylationWilliam D Bradley, Shilpi Arora, Jennifer Busby, et al.
Pageof 25